세계의 단백질체학 시장 : 계장별, 시약별, 서비스별, 소프트웨어별, 용도별 예측(-2029년)

The global proteomics market is estimated to reach USD 60.5 billion by 2029 from USD 33.6 billion in 2024, at a CAGR of 12.4% during the forecast period of 2024 to 2029.

"The spectroscopy segment holds dominant share in the proteomics market."

Based on the technology, the proteomics market is divided into spectroscopy, chromatography, electrophoresis, protein microarrays, X-ray crystallography, surface plasmon resonance, protein fractionation, and other technologies. The spectroscopy segment accounted for the largest share of 48.8% owing to factors such as technique is increased use in protein analysis, providing information about protein structure, size, shape, secondary or tertiary conformation, quantification, and interaction with other molecules, such as ligands, solutes, or other proteins.

"The immunoassay reagent dominated the reagent segments."

Based on reagent, the proteomics market is segmented into, protein microarray reagents, spectroscopy reagents, X-ray crystallography reagents, chromatography reagents, electrophoresis reagents, immunoassay reagents, and protein fractionation reagents. The immunoassay reagents accounted for the largest share of 26.5% of the reagent segment however spectroscopy reagent is anticipated to grow at significant CAGR during the forecast period. Factors like growing use of mass spectrometry-based techniques, development of high-throughput mass spectrometry techniques and increasing interest in personalized medicine are likely to drive the segmental growth.

"Biopharmaceutical companies segment is likely to grow at significant CAGR during the forecast period"

Based on end user, the proteomics market is segmented into hospitals, clinical laboratories, biopharmaceutical companies, academic & research institutes, and other end users. The biopharmaceutical companies segment accounted for the largest share of 39.1% of the proteomics market owing to rising focus of pharma giants on core activities like increasing R&D for the discovery and development of new molecules, identification of biomarkers and personalized medicine.

"Asia Pacific region estimated to show fastest growth rate."

Geographically, the proteomics market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. In 2023, North America accounted for the major share of the proteomics market. The Asia Pacific region is likely to grow at significant CAGR during the forecast period owing to various factors such as growing fields of proteomics and genomics research in conjunction with an increase in funding toward research studies. Rising investment by biopharmaceutical companies, growing research activity in the area of mAb-based therapeutics are likely to drive market expansion in the region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70%, and Demand Side - 30%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, MEA- 5%

List of Companies Profiled in the Report:

• Thermo fisher Scientific Inc (US)
• Agilent Technologies, Inc. (US)
• Merck KGaA (Germany)
• Danaher Corporation (US)
• Waters Corporation (US)
• Bio-Rad Laboratories, Inc. (US)
• Bruker Corporation (US)
• Revvity (US)
• Shimadzu Corporation (Japan)
• Illumina Inc (US)
• Promega Corporation (US)
• Eurofins Scientific (Luxembourg)
• Qiagen (Netherlands)
• Charles River Laboratories (US)
• Protagene (Germany)
• Creative Proteomics (US)
• Horiba (Japan)
• Sengenics Corporation LLC (US)
• Labvantage-Biomax GmbH (Germany)
• Cell Signaling Technology, Inc. (US)
• FIOS Genomics (UK)
• Azenta Life Sciences (US)
• Medgenome (India)
• Biognosys AG (Switzerland)
• Macrogen Inc (South Korea)

Research Coverage:

This report provides a detailed picture of the proteomics market. It aims at estimating the size and future growth potential of the market across different segments such as technology, reagent, service, software, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key Drivers (Growing demand for personalized medicines for clinical practices, Increased investments in proteomics research and development, Rising Application in Drug Discovery and Development and Government and Private Funding) restraints (High costs of proteomics instruments and technologies, Lack of standardization in proteomics techniques) opportunities (Advancements in Bioinformatics, Advancements in Single-Cell Proteomics and Collaborations and Partnerships) and challenges (Lack of data management/handling in proteomics research) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the proteomics market.
• Market Development: Comprehensive information about lucrative markets the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the proteomics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and products offerings of leading players like Thermo fisher Scientific Inc (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Waters Corporation (US), Bio-Rad Laboratories, Inc. (US), Bruker Corporation (US), Revvity (US), Shimadzu Corporation (Japan), Illumina Inc (US), Promega Corporation (US), Eurofins (Luxembourg), Qiagen (Netherlands), Charles River Laboratories (US), Protagene (Germany), Creative Proteomics (US), Horiba (Japan), Sengenics Corporation LLC (US), Labvantage-Biomax GmbH (Germany), Cell Signaling Technology, Inc. (US), FIOS Genomics (UK), Azenta Life Sciences (US), Medgenome (India), Biognosys AG (Switzerland) and Macrogen Inc (South Korea).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS CONSIDERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
  • 2.2.2 MNM REPOSITORY ANALYSIS
  • 2.2.3 PRIMARY INTERVIEWS
  • 2.2.4 SECONDARY RESEARCH
  • 2.2.5 INSIGHTS FROM PRIMARIES
  • 2.2.6 TOP-DOWN APPROACH
  • 2.2.7 MARKET GROWTH RATE PROJECTIONS
• 2.3 DATA TRIANGULATION
• 2.4 STUDY ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
• 2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PROTEOMICS MARKET OVERVIEW
• 4.2 NORTH AMERICA: PROTEOMICS MARKET, BY APPLICATION, 2023
• 4.3 SPECTROSCOPY INSTRUMENTATION TECHNOLOGY MARKET, BY TYPE, 2024 VS. 2029
• 4.4 PROTEOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing demand for personalized medicines in clinical practices
    • 5.2.1.2 High investments in pharmaceutical R&D
    • 5.2.1.3 Rising applications in drug discovery and development
    • 5.2.1.4 Increased private and government funding
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs of proteomics instruments and technologies
    • 5.2.2.2 Lack of standardization
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Advancements in bioinformatics
    • 5.2.3.2 Developments in single-cell proteomics research
    • 5.2.3.3 Increasing number of collaborations and strategic partnerships
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Lack of data management and handling
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Mass spectrometry
      • 5.4.1.1.1 Intact or top-down protein analysis
    • 5.4.1.2 Chromatography
    • 5.4.1.3 Protein microarrays
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Transcriptomics
    • 5.4.2.2 Metabolomics
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Single-cell proteomics
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE SELLING PRICE TREND FOR PROTEOMICS INSTRUMENTS MARKET, BY REGION, 2021-2023
  • 5.5.2 AVERAGE SELLING PRICE TREND OF PROTEOMICS INSTRUMENTS, BY REGION, 2023
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 SUPPLY CHAIN ANALYSIS
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 PROTEOMICS PRODUCT AND SERVICE PROVIDERS
  • 5.8.2 END USERS
  • 5.8.3 REGULATORY BODIES
• 5.9 PATENT ANALYSIS
  • 5.9.1 METHODOLOGY
  • 5.9.2 NUMBER OF PATENTS APPLIED AND GRANTED, BY DOCUMENT TYPE, 2013-2024
  • 5.9.3 INNOVATION AND PATENT APPLICATION
  • 5.9.4 TOP TEN PLAYERS WITH HIGHEST NUMBER OF APPLICATIONS
  • 5.9.5 TOP 10 PATENT OWNERS
  • 5.9.6 KEY PATENTS IN PROTEOMICS MARKET
• 5.10 TRADE ANALYSIS
  • 5.10.1 IMPORT DATA FOR CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS (HS CODE: 902720)
  • 5.10.2 EXPORT DATA FOR CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS (HS CODE: 902720)
  • 5.10.3 IMPORT DATA FOR MASS SPECTROMETERS (HS CODE: 902781)
  • 5.10.4 EXPORT DATA FOR MASS SPECTROMETERS (HS CODE: 902781)
• 5.11 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.12 REGULATORY LANDSCAPE
  • 5.12.1 REGULATORY SCENARIO
    • 5.12.1.1 North America
    • 5.12.1.2 Europe
    • 5.12.1.3 Asia Pacific
    • 5.12.1.4 Rest of the world
  • 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.13 INVESTMENT AND FUNDING SCENARIO
• 5.14 PORTER'S FIVE FORCES ANALYSIS
  • 5.14.1 THREAT OF NEW ENTRANTS
  • 5.14.2 THREAT OF SUBSTITUTES
  • 5.14.3 BARGAINING POWER OF BUYERS
  • 5.14.4 BARGAINING POWER OF SUPPLIERS
  • 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • 5.15.2 KEY BUYING CRITERIA
• 5.16 IMPACT OF AI/GEN AI ON PROTEOMICS MARKET

6 PROTEOMICS MARKET, BY INSTRUMENTATION TECHNOLOGY

• 6.1 INTRODUCTION
• 6.2 SPECTROSCOPY
  • 6.2.1 MASS SPECTROMETRY
    • 6.2.1.1 High specificity and technological advancements to propel segment growth
  • 6.2.2 NMR SPECTROSCOPY
    • 6.2.2.1 Accurate evaluation of physical, chemical, electronic, and structural information of proteins to aid segment growth
  • 6.2.3 CD SPECTROSCOPY
    • 6.2.3.1 Non-destructive and non-invasive techniques to examine changes in secondary protein structures
• 6.3 CHROMATOGRAPHY
  • 6.3.1 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
    • 6.3.1.1 High resolution, sensitivity, and reproducibility to spur segment growth
  • 6.3.2 ION CHROMATOGRAPHY
    • 6.3.2.1 High resolving power, simplicity, and controllability to separate and purify proteins
  • 6.3.3 AFFINITY CHROMATOGRAPHY
    • 6.3.3.1 High specificity for target proteins and easy identification of novel protein interactions to drive segment
  • 6.3.4 SUPERCRITICAL FLUID CHROMATOGRAPHY
    • 6.3.4.1 Ability to separate complex protein mixtures with high efficiency and speed to fuel segment growth
• 6.4 ELECTROPHORESIS
  • 6.4.1 GEL ELECTROPHORESIS
    • 6.4.1.1 Increasing demand for proteomics research and personalized medicine to boost segment growth
  • 6.4.2 CAPILLARY ELECTROPHORESIS
    • 6.4.2.1 Low diffusion coefficients of biomolecules and easy elimination of sample carryover between measurements to drive market
• 6.5 PROTEIN MICROARRAYS
  • 6.5.1 BIOCHIPS
    • 6.5.1.1 Lab-on-chips
      • 6.5.1.1.1 Rising focus on microfabrication and nanotechnology development to aid segment growth
    • 6.5.1.2 Protein chips
      • 6.5.1.2.1 Competitive advantage over conventional protein analysis tools to propel segment growth
  • 6.5.2 MICROARRAY INSTRUMENTS
    • 6.5.2.1 Integrated systems
      • 6.5.2.1.1 Integrated systems to enable high-throughput and reproducible analysis of proteins
    • 6.5.2.2 Microarray scanners
      • 6.5.2.2.1 Cost-effective and high-quality analysis to propel segment growth
    • 6.5.2.3 Arrayers
      • 6.5.2.3.1 Technological advancements to drive adoption of arrayers in large-scale projects
• 6.6 X-RAY CRYSTALLOGRAPHY
  • 6.6.1 RISING NEED FOR HIGH-RESOLUTION INFORMATION ON PROTEIN STRUCTURES TO AUGMENT MARKET GROWTH
• 6.7 SURFACE PLASMON RESONANCE
  • 6.7.1 INCREASING ABILITY TO BIND AFFINITIES AND KINETICS OF COMPLEXES TO PROPEL MARKET GROWTH
• 6.8 PROTEIN FRACTIONATION
  • 6.8.1 PROTEIN FRACTIONATION TO ENABLE EFFECTIVE SEPARATION OF PROTEINS IN COMPLEX MIXTURES
• 6.9 OTHER INSTRUMENTATION TECHNOLOGIES

7 PROTEOMICS MARKET, BY REAGENT

• 7.1 INTRODUCTION
• 7.2 IMMUNOASSAY REAGENTS
  • 7.2.1 NEED FOR RELIABLE, SPECIFIC, AND FAST DISEASE DETECTION AT EARLY STAGES TO FAVOR MARKET GROWTH
• 7.3 SPECTROSCOPY REAGENTS
  • 7.3.1 INCREASED ADOPTION OF HIGH-THROUGHPUT MASS SPECTROSCOPY-BASED TECHNIQUES TO AID MARKET GROWTH
• 7.4 CHROMATOGRAPHY REAGENTS
  • 7.4.1 BETTER ACCURACY AND LOWER DETECTION LIMITS TO FACILITATE SEGMENT GROWTH
• 7.5 PROTEIN MICROARRAY REAGENTS
  • 7.5.1 DEVELOPMENT OF NOVEL AND ADVANCED PROTEIN ANALYSIS REAGENTS TO PROPEL MARKET GROWTH
• 7.6 X-RAY CRYSTALLOGRAPHY REAGENTS
  • 7.6.1 EMERGENCE OF NEW TARGETS FOR DRUG DISCOVERY AND HIGH R&D INVESTMENTS TO SUPPORT MARKET GROWTH
• 7.7 ELECTROPHORESIS REAGENTS
  • 7.7.1 INCREASING DEMAND FOR 2D ELECTROPHORESIS TO AUGMENT MARKET GROWTH
• 7.8 PROTEIN FRACTIONATION REAGENTS
  • 7.8.1 RISING NEED FOR PROTEIN FRACTIONATION TECHNIQUES TO AUGMENT MARKET GROWTH
• 7.9 OTHER REAGENTS

8 PROTEOMICS MARKET, BY SERVICE

• 8.1 INTRODUCTION
• 8.2 CORE PROTEOMICS SERVICES
  • 8.2.1 PROTEIN IDENTIFICATION SERVICES
    • 8.2.1.1 Rising need for protein identification and molecular weight analysis to boost market growth
  • 8.2.2 QUANTITATIVE PROTEOMICS SERVICES
    • 8.2.2.1 Rapid and low-cost alternatives to help understand global protein expression and modifications
  • 8.2.3 PROTEIN CHARACTERIZATION SERVICES
    • 8.2.3.1 Characterization studies to help study complex protein structure, drug development, and PTMs
  • 8.2.4 PROTEIN PURIFICATION SERVICES
    • 8.2.4.1 Protein purification to maximize yield and purity of protein of interest
  • 8.2.5 PROTEIN SEPARATION SERVICES
    • 8.2.5.1 Technological advancements and use in downstream applications to augment segment growth
  • 8.2.6 PROTEIN SEQUENCING SERVICES
    • 8.2.6.1 Identification and characterization of PTMs to favor protein sequencing and research
  • 8.2.7 CUSTOM ASSAY SERVICES
    • 8.2.7.1 Custom assays to improve validation or consistency of protein analysis procedures
• 8.3 BIOINFORMATICS SERVICES
  • 8.3.1 LESSER ANALYSIS TIME AND FAVORABLE GOVERNMENT INITIATIVES TO SPUR MARKET GROWTH

9 PROTEOMICS MARKET, BY SOFTWARE

• 9.1 INTRODUCTION
  • 9.1.1 BIOINFORMATICS TOOLS
    • 9.1.1.1 Need for data management and advancements in bioinformatics to augment market growth
  • 9.1.2 BIOINFORMATICS DATABASES
    • 9.1.2.1 Need to store proteomics data and integrate other omics databases to drive market

10 PROTEOMICS MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 CLINICAL DIAGNOSTICS
  • 10.2.1 CANCER
    • 10.2.1.1 Rising prevalence of cancer to propel market growth
  • 10.2.2 INFECTIOUS DISEASES
    • 10.2.2.1 Technological advancements and need for effective disease diagnosis to support market growth
  • 10.2.3 DIABETES
    • 10.2.3.1 Need for advanced diagnostic technologies and high diabetes prevalence to aid market growth
  • 10.2.4 NEUROLOGICAL DISORDERS
    • 10.2.4.1 Growing target patient population and increasing research grants to fuel market growth
  • 10.2.5 AUTOIMMUNE DISEASES
    • 10.2.5.1 Increasing patient population and growing focus on immunology-based research to propel market growth
  • 10.2.6 CARDIOVASCULAR DISEASES
    • 10.2.6.1 High burden of cardiovascular diseases to spur adoption of reliable diagnostic tools
  • 10.2.7 OTHER CLINICAL DIAGNOSTIC APPLICATIONS
• 10.3 DRUG DISCOVERY & DEVELOPMENT
  • 10.3.1 TARGET DISCOVERY
    • 10.3.1.1 Increased demand for personalized medicine to support segment growth
  • 10.3.2 LEAD IDENTIFICATION
    • 10.3.2.1 Lead identification to be essential in drug discovery and characterization
  • 10.3.3 LEAD OPTIMIZATION
    • 10.3.3.1 Need for optimizing drug efficacy and safety to spur segment growth
  • 10.3.4 PRECLINICAL STUDIES
    • 10.3.4.1 Integration of proteomics in preclinical studies to refine drug safety and efficacy
• 10.4 OTHER APPLICATIONS

11 PROTEOMICS MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 BIOPHARMACEUTICAL COMPANIES
  • 11.2.1 LOW OPERATING COSTS AND RAPID DRUG ANALYSIS TO DRIVE MARKET
• 11.3 ACADEMIC AND RESEARCH INSTITUTES
  • 11.3.1 INCREASING RESEARCH FUNDING FOR PRECISION MEDICINE TO BOOST MARKET GROWTH
• 11.4 HOSPITALS
  • 11.4.1 GROWING PREVALENCE OF IMMUNODEFICIENCY DISEASES AND SERUM PROTEIN DISORDERS TO BOOST MARKET GROWTH
• 11.5 CLINICAL LABORATORIES
  • 11.5.1 INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO SUPPORT MARKET GROWTH
• 11.6 OTHER END USERS

12 PROTEOMICS MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 US to dominate North American proteomics market during study period
  • 12.2.3 CANADA
    • 12.2.3.1 Favorable government initiatives and high incidence of cancer to support market growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Well-established pharmaceutical industry and increased government funding to augment market growth
  • 12.3.3 UK
    • 12.3.3.1 Developed life science industry and increased academia-industry partnerships to augment market growth
  • 12.3.4 FRANCE
    • 12.3.4.1 High investments in life science R&D and increased demand for personalized therapeutics to aid market growth
  • 12.3.5 SWITZERLAND
    • 12.3.5.1 Well-established pharmaceutical and biotechnology industry and increased investments in life science R&D to drive market
  • 12.3.6 ITALY
    • 12.3.6.1 High private and public R&D funding and favorable government initiatives to favor market growth
  • 12.3.7 SPAIN
    • 12.3.7.1 Well-established network of research centers, universities, and hospitals to aid market growth
  • 12.3.8 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Rising government R&D investments and increasing focus on healthcare product manufacturing to fuel market growth
  • 12.4.3 JAPAN
    • 12.4.3.1 Large geriatric population and strong pharmaceutical research base to drive market
  • 12.4.4 INDIA
    • 12.4.4.1 Increasing focus on proteomics and genomic research to support market growth
  • 12.4.5 SOUTH KOREA
    • 12.4.5.1 Developed medical tourism and advanced healthcare infrastructure to propel market growth
  • 12.4.6 AUSTRALIA
    • 12.4.6.1 Favorable government initiatives and high R&D investments to favor market growth
  • 12.4.7 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Increasing contract research and manufacturing activities to drive market
  • 12.5.3 MEXICO
    • 12.5.3.1 Strong pharmaceutical industry and increased government support to augment market growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Saudi Arabia
      • 12.6.2.1.1 Increasing government healthcare investments and developing pharmaceuticals industry to boost market growth
    • 12.6.2.2 UAE
      • 12.6.2.2.1 High R&D expenditure and developed health infrastructure to drive market
    • 12.6.2.3 Rest of GCC Countries
  • 12.6.3 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 FAVORABLE GOVERNMENT INITIATIVES AND ADVANCEMENTS IN PERSONALIZED MEDICINES TO PROPEL MARKET GROWTH
  • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PROTEOMICS MARKET
• 13.3 REVENUE ANALYSIS, 2021-2023
• 13.4 MARKET SHARE ANALYSIS, 2023
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Instrumentation technology footprint
    • 13.5.5.3 Reagent footprint
    • 13.5.5.4 Service footprint
    • 13.5.5.5 Software footprint
    • 13.5.5.6 Region footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 THERMO FISHER SCIENTIFIC INC.
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products/Services/Solutions offered
  • 14.1.2 RECENT DEVELOPMENTS
    • 14.1.2.1 Product launches
    • 14.1.2.2 Deals
    • 14.1.2.3 MnM view
      • 14.1.2.3.1 Key strengths
      • 14.1.2.3.2 Strategic choices
      • 14.1.2.3.3 Weaknesses and competitive threats
  • 14.1.3 AGILENT TECHNOLOGIES, INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products/Services/Solutions offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches
      • 14.1.3.3.2 Deals
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 MERCK KGAA
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products/Services/Solutions offered
    • 14.1.4.3 MnM view
      • 14.1.4.3.1 Key strengths
      • 14.1.4.3.2 Strategic choices
      • 14.1.4.3.3 Weaknesses and competitive threats
  • 14.1.5 DANAHER CORPORATION
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products/Services/Solutions offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches
      • 14.1.5.3.2 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 SHIMADZU CORPORATION
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products/Services/Solutions offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches
      • 14.1.6.3.2 Expansions
    • 14.1.6.4 MnM view
      • 14.1.6.4.1 Key strengths
      • 14.1.6.4.2 Strategic choices
      • 14.1.6.4.3 Weaknesses and competitive threats
  • 14.1.7 WATERS CORPORATION
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products/Services/Solutions offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Product launches
      • 14.1.7.3.2 Deals
  • 14.1.8 BIO-RAD LABORATORIES, INC.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products/Services/Solutions offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches
  • 14.1.9 BRUKER
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products/Services/Solutions offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product launches
      • 14.1.9.3.2 Deals
  • 14.1.10 REVVITY
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products/Services/Solutions offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Deals
  • 14.1.11 ILLUMINA, INC.
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products/Services/Solutions offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Deals
  • 14.1.12 PROMEGA CORPORATION
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products/Services/Solutions offered
  • 14.1.13 EUROFINS SCIENTIFIC
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products/Services/Solutions offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Deals
  • 14.1.14 QIAGEN
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products/Services/Solutions offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Product launches
      • 14.1.14.3.2 Deals
  • 14.1.15 CHARLES RIVER LABORATORIES
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products/Services/Solutions offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Product launches
      • 14.1.15.3.2 Deals
  • 14.1.16 PROTAGENE
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products/Services/Solutions offered
• 14.2 OTHER PLAYERS
  • 14.2.1 CREATIVE PROTEOMICS, US
  • 14.2.2 HORIBA JAPAN LTD.
  • 14.2.3 SENGENICS CORPORATION LLC
  • 14.2.4 LABVANTAGE-BIOMAX GMBH
  • 14.2.5 FIOS GENOMICS
  • 14.2.6 AZENTA US, INC.
  • 14.2.7 MEDGENOME
  • 14.2.8 BIOGNOSYS AG
  • 14.2.9 MACROGEN, INC.
  • 14.2.10 CELL SIGNALING TECHNOLOGY, INC.

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS